Stephen Petranek’s career of over 40 years in the publishing world is marked by numerous prizes and awards for excellent writing on science, nature, technology, politics, economics and more. He has been editor-in-chief of the Miami Herald’s prestigious Sunday magazine, Tropic, and has covered a wide range of topics for Time Inc.’s Life magazine. His presentation 10 Ways the World Could End is one of the most original and most watched TED talks of all time.
Take a Triple-Digit Gain from This Neuroscience Company
This company’s Phase 2 trials received positive top-line results, sending the stock soaring. Let’s take advantage of this high, and cash out major gains.
Technology Innovation From Great Minds Around the Globe
Harnessing diversity of input from minds around the globe can be the difference between a good company and a great one. Stephen Petranek has more on the company developing artificial intelligence technology on a global level...
On Sale: Our Macular Degeneration Company
A Phase 2 trial flop doesn’t always mean we sell. See how we profit from the latest developments within this macular degeneration biotech company.
A New Dawn in Heart Disease Treatment
Heart disease is by far the most prominent killer in this country, but we can’t seem to make much progress on treatment. That could soon change. Stephen Petranek has more on the new approach to ending America’s No. 1 killer...
Kite Climbs on Good News, but Not by Much
The biotech position we sold yesterday saw gains with good news, but not all is as it seems. It’s still time to get out while we can.
Sell Alert! Offload This Immunotherapy Company for a Big Profit
Plus, we cut our losses on this biotech and the portfolio positions that are seeing a lot of pops lately.
Our Antibody Company Soars, but It’s Still Cheap
This biotech company is on a roll, but we’re just beginning to see the profits this company’s stock will ultimately bring us...
“Hey Siri, It’s Time for an Upgrade”
The software behind voice recognition systems is horribly stupid and inadequate.But it’s getting better. Stephen Petranek has more...
Ka-ching!
Positive results in a Phase 3 trial sent this portfolio position soaring over 50%...
Sell Alert — Cashing In on Triple-Digit Gains
We’re up about 160% on this stock, so here’s how to take advantage of our gains.